Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2025 per tanggal 31 Januari 2025 (67 artikel)
Publikasi Scopus 2025 per tanggal 31 Januari 2025 (67 artikel)
Chen, L.-T. (7409440415); Vogel, A. (7102618692); Hsu, C. (15756011800); Chen, M.-H. (35186849800); Fang, W. (16836058600); Pangarsa, E.A. (57204907532); Sharma, A. (57202966210); Ikeda, M. (35399280200); Park, J.O. (57977780300); Tan, C.K. (58288943100); Regala, E. (57196113996); Tai, D. (36180376300); Tanasanvimon, S. (23089332900); Charoentum, C. (6507550908); Chee, C.E. (15838788600); Lui, A. (57215365764); Sow, J. (59250312400); Oh, D.-Y. (8836932000); Ueno, M. (57197706804); Ramaswamy, A.
Corrigendum to “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer”: [ESMO Open 9 (2024) 103647] (ESMO Open (2024) 9(8), (S2059702924014169), (10.1016/j.esmoop.2024.103647))
2025
ESMO Open
10
1
104074
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85212439743&doi=10.1016%2fj.esmoop.2024.104074&partnerID=40&md5=e425b728d481eb513ddb8f389cd815f3
Kaohsiung Medical University Hospital, Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany; Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Haematology Medical Oncology Division, Department of Oncology, Faculty of Medicine, Diponegoro University/Dr. Kariadi Hospital, Semarang, Indonesia; Department of Medical Oncology, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, Saket, India; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Seoul, South Korea; Department of Oncology and Nuclear Medicine, Thomson Hospital Kota Damansara, Selangor, Petaling Jaya, Malaysia; Clinical Division Building, University of Santo Tomas Hospital, Manila, Sampaloc, Philippines; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore; Department of Internal Medicine, Metro Davao Medical and Research Center, Davao City, Philippines; Section of Medical Oncology, Department of Internal Medicine, Southern Philippines Medical Center, Davao City, Philippines; Department of Oncology, Curie Oncology Kuala Lumpur, Kuala Lumpur, Malaysia; Department of Internal Medicine, Seoul National University Hospital, Korea, Seoul, South Korea; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Parel, India; Division of Digestive Surgery, Department of General Surgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; Istituto Europeo di Oncologia, Milano, IRCCS, Milano, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; ESMO, Lugano, Switzerland; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC. Instituto de Salud Carlos III, Madrid, Spain; Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; INSERM U1279, Université Paris-Saclay, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, Villejuif, France
The authors report that in the original publication the ESMO-MCBS v1.1 scores for durvalumab-cisplatin-gemcitabine and pembrolizumab-cisplatin-gemcitabine are 4 and 1, respectively. The higher ESMO-MCBS v1.1 score for cisplatin-gemcitabine-durvalumab is due to the high 2-year OS gain observed with this regimen (14.2%). This was, however, based on only 9 patients (2.6% of the durvalumab-treated patients) who were still alive at that time. Thus, it should be noted that it does not currently provide evidence that durvalumab is vastly superior to pembrolizumab in combination with cisplatin-gemcitabine as both drugs incur similar clinical benefit with a HR OS of 0.75 and 0.83 and absolute median OS benefit of 1.6 and 1.8 months, respectively. Future updates to the ESMO-MCBS methodology will account for the proportion of study patients included in tail of the curve survival analyses, resulting in a lower MCBS score for durvalumab-cisplatin-gemcitabine. Recommendation 4a should read as follows: “Recommendation 4a. The combination of cisplatin-gemcitabine with durvalumab or pembrolizumab should be considered as standard of care in first-line BTC [I, A; ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score for durvalumab: 4; ESMO-MCBS v1.1 score for pembrolizumab: 1]. Cisplatin-gemcitabine-S1 is an alternative therapeutic option for fit patients [II, B].”[Figure presented] The revised Figure 1 Algorithm for the treatment of biliary tract cancer is given below. The authors would like to apologise for any inconvenience caused. © 2024 The Author(s)
erratum; human
Elsevier B.V.
20597029
Erratum
Q1
2498
931